All articles by Staff Writer
Staff Writer
Noul Participates in a Malaria Project Initiated by U.S. CDC with Kenya Medical Research Institute
On-Device AI healthcare company, Noul, announced that it will jointly participate in a malaria diagnosis project initiated by U.S. Centers for Disease Control and Prevention (CDC) with the Kenya Medical Research Institute (KEMRI).
Bio-Rad Extends Range of Anti-Biotherapeutic Antibodies to Accelerate Antibody Drug Development
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today launched four new anti-idiotypic antibodies to the following drugs: atezolizumab (Lemtrada), avelumab (Bavencio), obinutuzumab (Gazyvaro), and ocrelizumab (Ocrevus), extending its range of anti-biotherapeutic antibodies. The company also introduced its anti-monomethyl auristatin E (MMAE) biotherapeutic antibody range for bioanalysis.
Microbix Hosts Minister Nina Tangri to Open Capacity Expansions
Adds Product Development & QC Labs, Fully-Automated IVD Vial-Filling Capability
QIAGEN launches new QIAcuity digital PCR assays for microbial applications
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of 35 new wet-lab tested digital PCR Microbial DNA Detection Assays for its digital PCR (dPCR) platform QIAcuity, significantly enhancing its offerings in the field of microbial research. The new assays are available on QIAGEN’s comprehensive research platform GeneGlobe and are designed to target a wide range of pathogens responsible for tropical diseases, sexually transmitted infections (STIs) and urinary tract infections (UTIs), further solidifying QIAGEN’s position as a leader in microbial detection and analysis.
Nobel Laureate Professor Sir Martin Evans opens Molecular Devices’ Cardiff facility to manufacture patient-derived organoids for research and drug discovery
Molecular Devices is the world’s only company offering a service to manufacture standardized, quality-tested patient-derived organoids at a scale of many millions per batch
FIND and WHO sign new MoU to speed up innovation and access to quality diagnostics
FIND and the World Health Organization (WHO) have signed a new Memorandum of Understanding (MoU) that lays the foundation for accelerating innovation and achieving equitable accesss to quality diagnostics for people globally.
QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy number variation (CNV) analysis for use on its digital PCR platform QIAcuity and several other enhancements in its GeneGlobe Design and Analysis Hub, a comprehensive research platform that integrates pre-designed assays with a database of more than 10,000 biological entities including genes, miRNAs, and pathways. The new advancements aim to support customers with a wide range of assay customization options, from simple to complex and validated multiplex assays, while further improving the user experience.
Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions
Applied Biosystems™ CytoScan™ Dx and Chromosome Analysis Suite (ChAS) Dx software provide complete solution to support cytogenetic testing
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. This next-generation sequencing (NGS) test aims to support research into personalized medicine in multiple solid tumor types, including ovarian cancer and is expected to enhance decentralized testing capacities once a regulated product is developed with pharmaceutical partners. The project builds on the recently announced master collaboration agreement between the two companies.
QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision medicine
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QIAseq Multimodal DNA/RNA Lib Kit. The new kit enables seamless preparation of DNA and RNA libraries for next-generation sequencing (NGS), such as whole genome sequencing (WGS) and whole transcriptome sequencing (WTS), as well as downstream target enrichment based on hybrid-capture from a single sample.